MYOD1 and neoplasm: However, IF staining of tumor sections revealed that the tumor cells did not express MyoD1 and myogenin, markers of RMS cells (40), suggesting that this inconsistency between clinical SHP2 GOF mutation in patients and mouse sarcomagenesis could be associated with the origin and species of MSCs (Supplemental Figure 4D).